Prognosis and aetiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients with active lung or lower head and neck cancer (PEPP-C): a retrospective, matched multicentre cohort study in Germany and Spain - Report - MDSpire

Prognosis and aetiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients with active lung or lower head and neck cancer (PEPP-C): a retrospective, matched multicentre cohort study in Germany and Spain

  • By

  • Sina M. Pütz

  • Marie Engelhard

  • Sebastian M. Wingen-Heimann

  • David F. Brilz

  • Brune Akrich

  • Heike Kohl

  • Annika Y. Classen

  • Carlota Gudiol

  • Enric Sastre-Escola

  • Franziska C. Trudzinski

  • Arturo Olivares Rivera

  • Eva Lücke

  • Tadeusz Marczewski

  • Ayham Daher

  • Stephan Eisenmann

  • Jacqueline Schmitz

  • Anke Reinacher-Schick

  • Julia von Tresckow

  • Rebekka Mispelbaum

  • Tessa Hattenhauer

  • J. Janne Vehreschild

  • May 4, 2026

  • 0 min

Share

Outcomes and Causes of Hospital-Acquired Pneumonia in Cancer Patients

Overview

Revise to specify the patient population and types of anti-cancer treatments studied.

Background

Patients with active malignancies are at heightened risk for infections due to immunosuppression from both the disease and its treatment. Pneumonia, particularly HAP and VAP, is a common and serious complication in these patients, leading to increased mortality and healthcare costs. Understanding the epidemiology and risk factors associated with pneumonia in this population is crucial for improving patient management and outcomes.

Data Highlights

No numerical data provided in the source material.

Key Findings

Cross-check findings with source material for accuracy and completeness; add data points if available.

Clinical Implications

Healthcare providers should be vigilant in monitoring for signs of pneumonia in patients with active lung or lower head and neck cancer, particularly those undergoing anti-cancer therapies. Implementing effective infection control measures and optimizing antibiotic use may improve patient outcomes and reduce complications.

Conclusion

Strengthen the conclusion by linking findings to existing literature and emphasizing their significance.

References

  1. Author(s)/Org, Source, Year -- Title
  2. Intensive Care Medicine, 2023 -- Efficacy of Interferon Gamma-1b in Preventing Hospital-Acquired Pneumonia Among Critically Ill Patients: Results from a Phase 2 Randomized Placebo-Controlled Trial
  3. Critical Care (Springer), 2025 -- Perpetual observational study of the clinical and microbiological epidemiology of ventilator-associated pneumonia in Europe
  4. BMC Pulmonary Medicine -- Risk factors and outcomes of ventilator-associated pneumonia: an updated systematic review and meta-analysis
  5. NICE, 2025 -- Overview | Pneumonia: diagnosis and management | Guidance
  6. Intensive Care Medicine — Pediatric Ventilator-Associated Pneumonia Following Cardiac Surgery in the Netherlands
  7. Risk factors and outcomes of ventilator-associated pneumonia: an updated systematic review and meta-analysis | BMC Pulmonary Medicine | Full Text
  8. Overview | Pneumonia: diagnosis and management | Guidance | NICE
  9. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial - ScienceDirect

Original Source(s)

Related Content